Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health Cos. Inc. shares soared 6% in premarket trade Thursday, after the company said it expects third-quarter revenue to exceed $2.1 billion, ahead of the FactSet consensus of $1.99 billion.

Bausch Health shares jump 6% premarket after company offers upbeat revenue guidance

LAVAL, QC, Oct. 6, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that three poster presentations will feature the company's new silicone hydrogel (SiHy) daily disposable contact...

Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented On Bausch + Lomb Infuse™ Silicone Hydrogel Daily Disposable Contact Lenses During The American Academy Of Optometry Annual Meeting

Eton Pharmaceuticals Inc

After an initial rejection in 2019 and a string of delays following a refiling of the regulatory application, Eton Pharmaceuticals Inc's ETON 1.47% out-licensed allergic conjunctivitis ophthalmic solution is finally ready to see the light of the day.

Eton, Bausch Win FDA Approval For Preservative-Free Allergy Eyedrops

Bausch Health Companies Inc. (BHC) Management Presents at Morgan Stanley Global Healthcare Conference Call Transcript

LONDON--(BUSINESS WIRE)-- #EyewearMarket--The Global Eyewear Market will grow by USD 57.69 bn during 2020-2024

Global Eyewear Market- Featuring Bausch Health Companies Inc, Carl Zeiss AG, and De Rigo Vision Spa Among Others

LAVAL, Quebec, Sept. 10, 2020 /PRNewswire/ -- The Bausch Foundation ("Foundation"), which oversees and directs the charitable giving efforts of Bausch Health Companies Inc.

Bausch Foundation Releases Inaugural Activity Report

LAVAL, QC, Sept. 9, 2020 /PRNewswire/ -- Bausch Health Companies Inc.

Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Bausch (BHC) Down 19.1% Since Last Earnings Report: Can It Rebound?

Bausch Health Cos. Inc. BHC, -0.52% said Monday it will reduce debt by $100 million using cash generated from operations.

Bausch to reduce debt by $100 million using cash from operations

Bausch Health Is About To Fix The Balance Sheet And Create Massive Value

Trupanion

Having enough cash on hand during market sell-offs can allow investors to purchase both value and growth stocks at a bargain price. Here are two companies to consider.

Got $2,000 in Cash? Here Are the Top Healthcare Stocks to Buy Now

Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.

Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y

Bausch Health Companies Inc (BHC) CEO Joseph Papa on Q2 2020 Results - Earnings Call Transcript

Bausch's decision to carve out its eye care business into a stand-alone unit appears to be a hit with investors.

Why Bausch Health Companies Stock Is on Fire Today

Bausch Health Cos. shares BHC, +2.47% soared 27% in premarket trade Thursday, after the company said it is planning to spin off its eye-care business into a separate public company, confirming a Wall Street Journal report.

UPDATE: Bausch Health shares soar 27% premarket  after confirming to spin off eye-care business

Bausch Health Cos. shares BHC, +2.47% soared 23% in premarket trade Thursday, after a Wall Street Journal report that the company is planning to spin off its eye-care business from its core pharma operations, citing people familiar with the matter.

Bausch Health shares soar 23% premarket on report to spin off eye-care business

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Bausch Health (BHC) Might Surprise This Earnings Season

Bristol-Myers

Cooper Companies

Medtronic

Envista Holdings Corp

These 5 healthcare stocks look like the sector's best, with downside protection and room for price appreciation even if the market falters.

5 Healthcare Stocks for Good (Portfolio) Health

Bausch Health Cos. BHC, -3.07% will pay a $45 million fine to settle charges that the company misled investors in financial statements when it was known as Valeant Pharmaceuticals, according to the Securities and Exchange Commission late Friday.

Bausch Health to pay $45 million fine to settle Philidor charges

LAVAL, QC, July 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), f/k/a Valeant Pharmaceuticals International, Inc.

Bausch Health Resolves Legacy SEC Investigation

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bausch Health (BHC) Q2 Earnings Expected to Decline

LAVAL, QC, July 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") will release its second-quarter 2020 financial results on Thursday, Aug.

Bausch Health Companies Inc. Will Release Second-Quarter 2020 Financial Results On August 6

Gilead Sciences

Johnson & Johnson

Pfizer

Author Gerald Posner discusses his latest book, a history of the pharmaceutical industry.

Capital Interviews: Gerald Posner Discusses His New Book On Pharma, The Pandemic, And The Future Of The Industry

Bausch Health: Setting Its Sights On Eye Care

From 2015-2016, BHC lost roughly 90% of its stock value due to the Company’s destructive acquisition strategy—purchasing drugs and inflating their prices—which led to a highly leveraged business model.

News for Bausch Health Companies Inc Stock (BHC)